Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
But mixed data and a previous failure provide reasons to be cautious.
Novo moves into amyloidosis not long after Intellia made a splash here.
And four other potential targets that could make sense for the beleaguered group.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.